Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Meina T TangM E KeirR EricksonE G StefanichF K FuhT Ramirez-MontagutJ M McBrideD M DanilenkoPublished in: Alimentary pharmacology & therapeutics (2018)
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody that may have therapeutic potential for the treatment of IBD.